These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 25770459)

  • 1. A fluorescence in situ hybridization (FISH) microfluidic platform for detection of HER2 amplification in cancer cells.
    Kao KJ; Tai CH; Chang WH; Yeh TS; Chen TC; Lee GB
    Biosens Bioelectron; 2015 Jul; 69():272-9. PubMed ID: 25770459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
    Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
    Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FISH in chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool.
    Perez-Toralla K; Mottet G; Guneri ET; Champ J; Bidard FC; Pierga JY; Klijanienko J; Draskovic I; Malaquin L; Viovy JL; Descroix S
    Lab Chip; 2015 Feb; 15(3):811-22. PubMed ID: 25474258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
    Han X; Shi Y; Ma L; Lyu Z; Yang H; Yao J; Li J; Li B; Qin Y
    Chin Med J (Engl); 2014; 127(2):246-53. PubMed ID: 24438611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.
    Schlemmer BO; Sorensen BS; Overgaard J; Olsen KE; Gjerdrum LM; Nexo E
    Scand J Clin Lab Invest; 2004; 64(5):511-22. PubMed ID: 15276916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
    Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
    Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH.
    Yoon N; Do IG; Cho EY
    APMIS; 2014 Sep; 122(9):755-60. PubMed ID: 24372629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study.
    Aimi F; Procopio MG; Alvarez Flores MT; Brouland JP; Piazzon N; Brajkovic S; Dupouy DG; Gijs M; de Leval L
    Virchows Arch; 2019 Sep; 475(3):313-323. PubMed ID: 31267199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer.
    Dupouy DG; Ciftlik AT; Fiche M; Heintze D; Bisig B; de Leval L; Gijs MA
    Sci Rep; 2016 Feb; 6():20277. PubMed ID: 26856369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FISH and chips: a review of microfluidic platforms for FISH analysis.
    Rodriguez-Mateos P; Azevedo NF; Almeida C; Pamme N
    Med Microbiol Immunol; 2020 Jun; 209(3):373-391. PubMed ID: 31965296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.
    Horii R; Matsuura M; Iwase T; Ito Y; Akiyama F
    Breast Cancer; 2014 Sep; 21(5):598-604. PubMed ID: 23307494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rate.
    Sarode VR; Xiang QD; Christie A; Collins R; Rao R; Leitch AM; Euhus D; Haley B
    Arch Pathol Lab Med; 2015 Jul; 139(7):922-8. PubMed ID: 26125432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases.
    Theodosiou Z; Kasampalidis IN; Karayannopoulou G; Kostopoulos I; Bobos M; Bevilacqua G; Aretini P; Starita A; Lyroudia K; Pitas I
    Breast; 2008 Feb; 17(1):80-4. PubMed ID: 17889539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.